Zakaria Hamdan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zakaria Hamdan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Zaher Nazzal
An-Najah National University
15 shared publications Ahmad Enaya
Department of Internal Medicine, An-Najah National University Hospital, Nablus, Palestine
4 shared publicationsAlaa Sarsour
Affiliation Kidney and Dialysis Section, An-Najah National University Hospital, Nablus, Palestine
3 shared publicationsAmeed Taher
Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
2 shared publicationsMazen Abdalla
Affiliations Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University. Nablus, Palestine, Department of Orthopedics, An-Najah National University Hospital, Nablus, Palestine
2 shared publications- Osama Sawalmeh
Faculty of Medicine, Arab American University, Jenin P.O. Box 240, Palestine
2 shared publications
Latest Publications
- Open Access
- 21 October 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (10)
Pluralibacter gergoviae: an uncommon pathogen in peritoneal dialysis-related peritonitis: the second documented case worldwide
Peritonitis remains a serious complication in patients undergoing peritoneal dialysis, often caused by common organisms such as Staphylococcus aureus. However, rare pathogens may also play a role. We report a case of peritonitis in a 41-year-old female on continuous ambulatory peritoneal dialysis, in whom Pluralibacter gergoviae was identified as the causative organism. The patient presented with abdominal pain and cloudy dialysate but remained hemodynamically stable. Peritoneal fluid analysis revealed elevated white cell counts, and culture Pluralibacter gergoviae, which was sensitive to multiple antibiotics. Initial empiric therapy was adjusted accordingly, leading to clinical and laboratory improvement. This is the second reported case of Pluralibacter gergoviae-related peritonitis in the literature. This case underscores the importance of recognizing uncommon pathogens in peritoneal dialysis-related infections and the role of prompt microbiological diagnosis in guiding targeted therapy. Increased awareness and reporting of such cases are essential to enhance understanding and optimize patient management.
- 21 October 2025
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2025 (10)
Open AccessPluralibacter gergoviae: an uncommon pathogen in peritoneal dialysis-related peritonitis: the second documented case worldwide
Peritonitis remains a serious complication in patients undergoing peritoneal dialysis, often caused by common organisms such as Staphylococcus aureus. However, rare pathogens may also play a role. We report a case of peritonitis in a 41-year-old female on continuous ambulatory peritoneal dialysis, in whom Pluralibacter gergoviae was identified as the causative organism. The patient presented with abdominal pain and cloudy dialysate but remained hemodynamically stable. Peritoneal fluid analysis revealed elevated white cell counts, and culture Pluralibacter gergoviae, which was sensitive to multiple antibiotics. Initial empiric therapy was adjusted accordingly, leading to clinical and laboratory improvement. This is the second reported case of Pluralibacter gergoviae-related peritonitis in the literature. This case underscores the importance of recognizing uncommon pathogens in peritoneal dialysis-related infections and the role of prompt microbiological diagnosis in guiding targeted therapy. Increased awareness and reporting of such cases are essential to enhance understanding and optimize patient management.
- Open Access
- 2 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 510
Exploring the relationship between intravenous iron therapy and troponin T levels in hemodialysis patients: a cross-sectional study
Cardiac troponin T is often elevated in hemodialysis patients, even without apparent heart disease. Cardiac troponin T has been used to predict mortality and morbidity among asymptomatic dialysis patients. However, only a single retrospective study has reported that higher IV iron use was associated with higher troponin levels; therefore, it remains unclear whether IV iron therapy could influence troponin levels and thus affect patients’ outcomes. A cross-sectional study was conducted from February 2023 to October 2024 at the dialysis unit. We included 244 patients who had been on hemodialysis for more than 3 months, were on IV iron therapy, and were aged 18 years or older. High-sensitivity troponin T level (h-cTnT) was measured before the start of the dialysis session, and patients were stratified into two groups based on h-cTnT (≤ 60 ng/L and > 60 ng/L). Among 224 hemodialysis patients (137 male, 87 female; mean age of 59.96 ± 13.02 years). The average IV iron dose was 255.5 ± 143.0 mg/month. hs-TnT levels averaged 90.5 ± 89.4 ng/L, with 58.5% (131 patients) have h-cTnT level > 60 ng/L. No significant relationship between IV iron and h-cTnT was found. However, higher h-cTnT levels were significantly associated with male gender, age, ischemic heart disease, cerebrovascular accidents, statin use, and doxazosin. The > 60 ng/L group had a significantly lower processed blood volume (p = 0.038), shorter effective treatment time (p = 0.021), and lower KT/V urea (p = 0.008). Albumin levels were also lower in this group (p = 0.018). There is no statistically significant relationship between h-cTnT and IV iron. However, these results don’t eliminate the importance of IV iron therapy in hemodialysis patients. Not applicable.
- 2 September 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 510
Open AccessExploring the relationship between intravenous iron therapy and troponin T levels in hemodialysis patients: a cross-sectional study
Cardiac troponin T is often elevated in hemodialysis patients, even without apparent heart disease. Cardiac troponin T has been used to predict mortality and morbidity among asymptomatic dialysis patients. However, only a single retrospective study has reported that higher IV iron use was associated with higher troponin levels; therefore, it remains unclear whether IV iron therapy could influence troponin levels and thus affect patients’ outcomes. A cross-sectional study was conducted from February 2023 to October 2024 at the dialysis unit. We included 244 patients who had been on hemodialysis for more than 3 months, were on IV iron therapy, and were aged 18 years or older. High-sensitivity troponin T level (h-cTnT) was measured before the start of the dialysis session, and patients were stratified into two groups based on h-cTnT (≤ 60 ng/L and > 60 ng/L). Among 224 hemodialysis patients (137 male, 87 female; mean age of 59.96 ± 13.02 years). The average IV iron dose was 255.5 ± 143.0 mg/month. hs-TnT levels averaged 90.5 ± 89.4 ng/L, with 58.5% (131 patients) have h-cTnT level > 60 ng/L. No significant relationship between IV iron and h-cTnT was found. However, higher h-cTnT levels were significantly associated with male gender, age, ischemic heart disease, cerebrovascular accidents, statin use, and doxazosin. The > 60 ng/L group had a significantly lower processed blood volume (p = 0.038), shorter effective treatment time (p = 0.021), and lower KT/V urea (p = 0.008). Albumin levels were also lower in this group (p = 0.018). There is no statistically significant relationship between h-cTnT and IV iron. However, these results don’t eliminate the importance of IV iron therapy in hemodialysis patients. Not applicable.
- Open Access
- 18 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2479236
Impact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine
This study aims to evaluate the impact of COVID-19 on the progression of CKD in non-dialysis patients and its relation to clinical outcomes in Palestine. We conducted a retrospective cohort study that followed non-dialysis CKD patients receiving treatment at outpatient clinics in governmental hospitals. Out of the 248 CKD patients who met the inclusion criteria, 98 were diagnosed with COVID-19 between March 2020 and March 2022. We collected data at three distinct time intervals, both prior to and after their COVID-19 infection. We examined the decline in eGFR and gathered demographic information, hospitalization, and mortality rates. The drop in eGFR was recorded 15 months from baseline. The mean age of the patients was 55 years, with 55.6% being male. Patients diagnosed with COVID-19 faced a significantly higher risk of rapid deterioration in eGFR, with a 3.7-fold increase compared to those without COVID-19 (ap-value: p-value: 0.005; aOR: 4.4; 95% CI: 1.6-12.4), 13.3 times higher rates of dialysis initiation within 15 months post-baseline (ap-value: p-value: <0.001; aOR: 3.5; 95% CI: 1.8-6.7) compared to the COVID-19 negative group. CKD patients who contract COVID-19 experience a more rapid decline in kidney function, leading to worse health outcomes, including increased mortality rates, a greater need for dialysis, and higher hospitalization rates.
- 18 March 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2479236
Open AccessImpact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine
This study aims to evaluate the impact of COVID-19 on the progression of CKD in non-dialysis patients and its relation to clinical outcomes in Palestine. We conducted a retrospective cohort study that followed non-dialysis CKD patients receiving treatment at outpatient clinics in governmental hospitals. Out of the 248 CKD patients who met the inclusion criteria, 98 were diagnosed with COVID-19 between March 2020 and March 2022. We collected data at three distinct time intervals, both prior to and after their COVID-19 infection. We examined the decline in eGFR and gathered demographic information, hospitalization, and mortality rates. The drop in eGFR was recorded 15 months from baseline. The mean age of the patients was 55 years, with 55.6% being male. Patients diagnosed with COVID-19 faced a significantly higher risk of rapid deterioration in eGFR, with a 3.7-fold increase compared to those without COVID-19 (ap-value: p-value: 0.005; aOR: 4.4; 95% CI: 1.6-12.4), 13.3 times higher rates of dialysis initiation within 15 months post-baseline (ap-value: p-value: <0.001; aOR: 3.5; 95% CI: 1.8-6.7) compared to the COVID-19 negative group. CKD patients who contract COVID-19 experience a more rapid decline in kidney function, leading to worse health outcomes, including increased mortality rates, a greater need for dialysis, and higher hospitalization rates.
- Open Access
- 10 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Decline in eGFR and mortality among type II diabetic patients: a 3-year prospective cohort study from Palestine
Diabetic nephropathy is a significant complication of diabetes and a leading cause of chronic kidney disease (CKD) globally. This study aimed to assess the decline of renal function and all-cause mortality and identify the contributing risk factors among Palestinian patients with diabetes. The study employed a prospective cohort design, enrolling 311 patients with type 2 diabetes mellitus (T2DM) attending primary health care centers in Palestine. Baseline data were collected in 2018 to determine the prevalence of CKD in patients with T2DM. Subsequently, the patients were followed up for three years to assess renal function and identify significant associated risk factors. The primary outcomes examined were estimated glomerular filtration rate (eGFR) decline and all-cause mortality. During the three-year follow-up, 37.5% of the patients experienced eGFR decline, averaging 4.2 ml/min/1.73 m² per year. Males showed a significant association with eGFR decline with 5 times higher risk of developing eGFR decline. Hypertensive patients were 2.4 times more likely to experience decline. Regarding all-cause mortality, 14.1% of the patients died, with an incidence rate of 51.3 deaths per 1000 person-years. The risk of all-cause mortality was 5.5 times greater for patients with impaired renal function at baseline and 10.8 times greater for patients who had eGFR decline. This study highlights the importance of early detection of CKD in patients with diabetes, prompting more comprehensive management of risk factors related to eGFR decline and mortality. Furthermore, it underscores the need for future research in this patient population, including investigations about other relevant risk factors and the impact of different medications, such as anti-diabetic and antihypertensive medications, on the GFR decline and mortality rate.
- 10 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Open AccessDecline in eGFR and mortality among type II diabetic patients: a 3-year prospective cohort study from Palestine
Diabetic nephropathy is a significant complication of diabetes and a leading cause of chronic kidney disease (CKD) globally. This study aimed to assess the decline of renal function and all-cause mortality and identify the contributing risk factors among Palestinian patients with diabetes. The study employed a prospective cohort design, enrolling 311 patients with type 2 diabetes mellitus (T2DM) attending primary health care centers in Palestine. Baseline data were collected in 2018 to determine the prevalence of CKD in patients with T2DM. Subsequently, the patients were followed up for three years to assess renal function and identify significant associated risk factors. The primary outcomes examined were estimated glomerular filtration rate (eGFR) decline and all-cause mortality. During the three-year follow-up, 37.5% of the patients experienced eGFR decline, averaging 4.2 ml/min/1.73 m² per year. Males showed a significant association with eGFR decline with 5 times higher risk of developing eGFR decline. Hypertensive patients were 2.4 times more likely to experience decline. Regarding all-cause mortality, 14.1% of the patients died, with an incidence rate of 51.3 deaths per 1000 person-years. The risk of all-cause mortality was 5.5 times greater for patients with impaired renal function at baseline and 10.8 times greater for patients who had eGFR decline. This study highlights the importance of early detection of CKD in patients with diabetes, prompting more comprehensive management of risk factors related to eGFR decline and mortality. Furthermore, it underscores the need for future research in this patient population, including investigations about other relevant risk factors and the impact of different medications, such as anti-diabetic and antihypertensive medications, on the GFR decline and mortality rate.
- Open Access
- 24 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0317132
Factors associated with malnutrition inflammation score among hemodialysis patients: A cross-sectional investigation in tertiary care hospital, Palestine
Malnutrition is a prevalent complication in hemodialysis patients and is associated with increased mortality and morbidity. This study aimed to identify the risk factors associated with malnutrition among hemodialysis patients including patient’s general characteristics, functional status, and dietary intake. This study involved hemodialysis patients in An-Najah National University Hospital at Nablus/Palestine. An interview-based questionnaire was used to collect data related to sociodemographic, lifestyle, hemodialysis, medical history, anthropometrics, biochemical indices, dietary data using 3-days diet recall, and functional status. Malnutrition-inflammation score tool (MIS) was used for malnutrition screening of the studied patients. The study involved 188 patients, with a mean age of 57.8±14 years. A total of 28.2% participants are reported malnourished. Malnutrition was significantly associated with being female (p = 0.001), unemployed (p = 0.009), nonsmoker or ex-smoker (p = 0.018). Patients with CVDs (p = 0.006), higher months on dialysis (p = 0.002), lower BMI (p = 0.018), and using catheter for dialysis access are more likely to develop malnutrition (p = 0.018). Furthermore, patients with poor functional status (poor handgrip strength (p<0.001), inability to walk (p<0.001), needing help in daily activity or in transfer (p<0.001)) were significantly associated with malnutrition. Additionally, malnutrition was significantly higher among patients who does not meet their recommended calorie intake (p = 0.008), whose sodium intake within recommendation (p = 0.049), patients with low levels of hemoglobin (p = 0.022), albumin (p<0.001), TIBC (p = 0.002), phosphate (p<0.001), and patients with higher levels of ferritin (p<0.001). Higher months on dialysis (Exp(B) = 1.02), unmet calorie intake (Exp(B) = 4.3), needing help in daily activities (Exp(B) = 0.238), and low albumin level (Exp(B) = 0.048) were the independent predictors of malnutrition. This study highlights the significant association between malnutrition and various demographic, clinical, functional, and dietary factors in hemodialysis patients, revealing the burden of malnutrition during HD. It also necessitates targeted intervention to address these risk factors and improve nutritional status and the overall health outcomes of HD patients.
- 24 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0317132
Open AccessFactors associated with malnutrition inflammation score among hemodialysis patients: A cross-sectional investigation in tertiary care hospital, Palestine
Malnutrition is a prevalent complication in hemodialysis patients and is associated with increased mortality and morbidity. This study aimed to identify the risk factors associated with malnutrition among hemodialysis patients including patient’s general characteristics, functional status, and dietary intake. This study involved hemodialysis patients in An-Najah National University Hospital at Nablus/Palestine. An interview-based questionnaire was used to collect data related to sociodemographic, lifestyle, hemodialysis, medical history, anthropometrics, biochemical indices, dietary data using 3-days diet recall, and functional status. Malnutrition-inflammation score tool (MIS) was used for malnutrition screening of the studied patients. The study involved 188 patients, with a mean age of 57.8±14 years. A total of 28.2% participants are reported malnourished. Malnutrition was significantly associated with being female (p = 0.001), unemployed (p = 0.009), nonsmoker or ex-smoker (p = 0.018). Patients with CVDs (p = 0.006), higher months on dialysis (p = 0.002), lower BMI (p = 0.018), and using catheter for dialysis access are more likely to develop malnutrition (p = 0.018). Furthermore, patients with poor functional status (poor handgrip strength (p<0.001), inability to walk (p<0.001), needing help in daily activity or in transfer (p<0.001)) were significantly associated with malnutrition. Additionally, malnutrition was significantly higher among patients who does not meet their recommended calorie intake (p = 0.008), whose sodium intake within recommendation (p = 0.049), patients with low levels of hemoglobin (p = 0.022), albumin (p<0.001), TIBC (p = 0.002), phosphate (p<0.001), and patients with higher levels of ferritin (p<0.001). Higher months on dialysis (Exp(B) = 1.02), unmet calorie intake (Exp(B) = 4.3), needing help in daily activities (Exp(B) = 0.238), and low albumin level (Exp(B) = 0.048) were the independent predictors of malnutrition. This study highlights the significant association between malnutrition and various demographic, clinical, functional, and dietary factors in hemodialysis patients, revealing the burden of malnutrition during HD. It also necessitates targeted intervention to address these risk factors and improve nutritional status and the overall health outcomes of HD patients.
- Open Access
- 26 November 2024
- Published by Qeios Ltd
Review of: "Case Report: Urinary Proteomic Analysis of Exercise-Induced Rhabdomyolysis with Acute Kidney Injury"
Interesting case, very descriptive, and a novel idea to review associated proteins with rhabdo and AKI. I did not notice a urine analysis and specifically an evaluation for hematuria and its resolution and trend. The initial workup must include a uri...
- 26 November 2024
- Published by Qeios Ltd
Open AccessReview of: "Case Report: Urinary Proteomic Analysis of Exercise-Induced Rhabdomyolysis with Acute Kidney Injury"
Interesting case, very descriptive, and a novel idea to review associated proteins with rhabdo and AKI. I did not notice a urine analysis and specifically an evaluation for hematuria and its resolution and trend. The initial workup must include a uri...
- 26 July 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (6) , 1332-1340
Worsening of Diabetes Control Measures and Decreased Kidney Function in Pre-Diabetic Kidney Donors Compared to Non-Diabetic Donors Whose BMI Before Kidney Donation was Above 30
- 26 July 2024
- Published by Elsevier in Transplantation Proceedings
- Vol. 56 (6) , 1332-1340
Worsening of Diabetes Control Measures and Decreased Kidney Function in Pre-Diabetic Kidney Donors Compared to Non-Diabetic Donors Whose BMI Before Kidney Donation was Above 30
- Open Access
- 16 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0301814
Bone mineral density and related clinical and laboratory factors in peritoneal dialysis patients: Implications for bone health management
Background: End-stage renal disease (ESRD) patients often experience accelerated bone turnover, leading to osteoporosis and osteopenia. This study aimed to determine the prevalence of osteoporosis in Peritoneal Dialysis (PD) patients using bone mineral density (BMD) measurements obtained through dual-energy X-ray absorptiometry (DEXA) scan and to explore any possible associations with clinical and biochemical factors. Methods: In this cross-sectional study, we enrolled 76 peritoneal dialysis patients from the dialysis center at An-Najah National University Hospital in Nablus, Palestine. We used the DEXA scan to measure BMD at the lumbar spine and hip, with values expressed as T-scores. We conducted a multivariate analysis to explore the relationship between BMD and clinical and biochemical parameters. Results: Over half (52.6%) of the PD patients had osteoporosis, with a higher prevalence observed among patients with lower BMI (p<0.001). Higher alkaline phosphatase levels were found among osteoporotic patients compared to non-osteoporotic patients (p = 0.045). Vitamin D deficiency was also prevalent in this population, affecting 86.6% of patients. No significant correlation was found between 25 vitamin D levels and BMD. No significant correlation was found between Parathyroid hormone (PTH) levels and BMD. Conclusion: A notable proportion of PD patients experience reduced BMD. Our study found no correlation between vitamin D levels and BMD, but it highlighted the significant vitamin D deficiency in this population. Furthermore, our analysis indicated a positive correlation between BMI and BMD, especially in the femoral neck area. This underscores the significance of addressing bone health in PD patients to mitigate the risk of fractures and improve their overall well-being.
- 16 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0301814
Open AccessBone mineral density and related clinical and laboratory factors in peritoneal dialysis patients: Implications for bone health management
Background: End-stage renal disease (ESRD) patients often experience accelerated bone turnover, leading to osteoporosis and osteopenia. This study aimed to determine the prevalence of osteoporosis in Peritoneal Dialysis (PD) patients using bone mineral density (BMD) measurements obtained through dual-energy X-ray absorptiometry (DEXA) scan and to explore any possible associations with clinical and biochemical factors. Methods: In this cross-sectional study, we enrolled 76 peritoneal dialysis patients from the dialysis center at An-Najah National University Hospital in Nablus, Palestine. We used the DEXA scan to measure BMD at the lumbar spine and hip, with values expressed as T-scores. We conducted a multivariate analysis to explore the relationship between BMD and clinical and biochemical parameters. Results: Over half (52.6%) of the PD patients had osteoporosis, with a higher prevalence observed among patients with lower BMI (p<0.001). Higher alkaline phosphatase levels were found among osteoporotic patients compared to non-osteoporotic patients (p = 0.045). Vitamin D deficiency was also prevalent in this population, affecting 86.6% of patients. No significant correlation was found between 25 vitamin D levels and BMD. No significant correlation was found between Parathyroid hormone (PTH) levels and BMD. Conclusion: A notable proportion of PD patients experience reduced BMD. Our study found no correlation between vitamin D levels and BMD, but it highlighted the significant vitamin D deficiency in this population. Furthermore, our analysis indicated a positive correlation between BMI and BMD, especially in the femoral neck area. This underscores the significance of addressing bone health in PD patients to mitigate the risk of fractures and improve their overall well-being.
- Open Access
- 26 January 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-8
Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function
Background: Patients taking SGLT-2 inhibitors may experience delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and higher survival rates. We aimed to evaluate the possible effects of Dapagliflozin in changing the peritoneal solute transfer rate, reducing peritoneal glucose absorption, and, hence, increasing ultrafiltration. Methodology: A pilot pre-post interventional study was used to evaluate 20 patients on continuous ambulatory peritoneal dialysis (CAPD) enrolled in a one-month self-controlled study [Trial#: NCT04923295]. Inclusion criteria included being over 18, and having a Peritoneal Dialysis (PD) vintage of at least six months. All participants were classified as having high or average high transport status based on their Peritoneal Equilibrium Test with a D0/D4 > 0.39. and using at least two exchanges with 2.35% dextrose over the previous three months before enrollment. Results: Following the treatment, 13 patients had an increase in median D4/D0 from 0.26 [0.17–0.38] to 0.31 [0.23–0.40], while seven patients had a decline from 0.28 [0.17–0.38] to 0.23 [0.14–0.33]. Additionally, nine patients had a decrease in median D/P from 0.88 [0.67–0.92] to 0.81 [0.54–0.85], while 11 patients had an increase from 0.70 [0.6–0.83] to 0.76 [0.63–0.91]. Conclusion: According to the findings of this study, Dapagliflozin usage in peritoneal dialysis patients did not result in a reduction in glucose absorption across the peritoneal membrane. Additionally, Dapagliflozin was also associated with a small increase in sodium dip, a decrease in peritoneal VEGF, and a decrease in systemic IL-6 levels all of which were not statistically significant. Further large-scale studies are required to corroborate these conclusions.
- 26 January 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-8
Open AccessDapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function
Background: Patients taking SGLT-2 inhibitors may experience delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and higher survival rates. We aimed to evaluate the possible effects of Dapagliflozin in changing the peritoneal solute transfer rate, reducing peritoneal glucose absorption, and, hence, increasing ultrafiltration. Methodology: A pilot pre-post interventional study was used to evaluate 20 patients on continuous ambulatory peritoneal dialysis (CAPD) enrolled in a one-month self-controlled study [Trial#: NCT04923295]. Inclusion criteria included being over 18, and having a Peritoneal Dialysis (PD) vintage of at least six months. All participants were classified as having high or average high transport status based on their Peritoneal Equilibrium Test with a D0/D4 > 0.39. and using at least two exchanges with 2.35% dextrose over the previous three months before enrollment. Results: Following the treatment, 13 patients had an increase in median D4/D0 from 0.26 [0.17–0.38] to 0.31 [0.23–0.40], while seven patients had a decline from 0.28 [0.17–0.38] to 0.23 [0.14–0.33]. Additionally, nine patients had a decrease in median D/P from 0.88 [0.67–0.92] to 0.81 [0.54–0.85], while 11 patients had an increase from 0.70 [0.6–0.83] to 0.76 [0.63–0.91]. Conclusion: According to the findings of this study, Dapagliflozin usage in peritoneal dialysis patients did not result in a reduction in glucose absorption across the peritoneal membrane. Additionally, Dapagliflozin was also associated with a small increase in sodium dip, a decrease in peritoneal VEGF, and a decrease in systemic IL-6 levels all of which were not statistically significant. Further large-scale studies are required to corroborate these conclusions.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 3007-3017
Comprehensive Assessment of Colistin Induced Nephrotoxicity: Incidence, Risk Factors and Time Course
Purpose: In recent years, the emergence of multidrug-resistant (MDR) microorganisms had caused the resurgence of colistin use after it was previously abandoned due to its side effects, nephrotoxicity in particular. However, the specific incidence of colistin-induced nephrotoxicity varies in reports with different populations. This study aims to assess the incidence of colistin-associated nephrotoxicity and the associated risk factors. Patients and Methods: This study was on 178 patients who received colistin for more than 48 hours during the years 2019– 2022, who were followed up for 14 days after the initiation of colistin, and demographic and clinical data were gained from medical reports. Logistic regression was used to assess the relationship between nephrotoxicity and study variables. Results: The incidence of nephrotoxicity was 44.9% (95% confidence interval (CI); 37% to 53%), and the overall mortality was 33%, with a significantly higher level among patients with nephrotoxicity. The significant risk factors for nephrotoxicity after adjustment were; higher weights (OR = 1.1, 95% CI; 0.03– 1.2), P-value: 0.006, and the combination with carbapenem showed a significant protective effect (OR = 0.09, 95% CI; 0.01– 0.8), P-value: 0.03. The severity, according to KDIGO classification, was stage 1 (47%), stage 2 (21%), and stage 3 (31%). Higher stages had earlier onset acute kidney injury, a lower percentage of returning to baseline, and exposure to a higher colistin dose. Conclusion: Colistin-induced nephrotoxicity was a frequent issue associated with higher weights, mitigated by the combination with carbapenems. While higher colistin dosages, and earlier onset AKI, were linked to the progression to higher AKI stages and the need for dialysis.
- 1 May 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 3007-3017
Open AccessComprehensive Assessment of Colistin Induced Nephrotoxicity: Incidence, Risk Factors and Time Course
Purpose: In recent years, the emergence of multidrug-resistant (MDR) microorganisms had caused the resurgence of colistin use after it was previously abandoned due to its side effects, nephrotoxicity in particular. However, the specific incidence of colistin-induced nephrotoxicity varies in reports with different populations. This study aims to assess the incidence of colistin-associated nephrotoxicity and the associated risk factors. Patients and Methods: This study was on 178 patients who received colistin for more than 48 hours during the years 2019– 2022, who were followed up for 14 days after the initiation of colistin, and demographic and clinical data were gained from medical reports. Logistic regression was used to assess the relationship between nephrotoxicity and study variables. Results: The incidence of nephrotoxicity was 44.9% (95% confidence interval (CI); 37% to 53%), and the overall mortality was 33%, with a significantly higher level among patients with nephrotoxicity. The significant risk factors for nephrotoxicity after adjustment were; higher weights (OR = 1.1, 95% CI; 0.03– 1.2), P-value: 0.006, and the combination with carbapenem showed a significant protective effect (OR = 0.09, 95% CI; 0.01– 0.8), P-value: 0.03. The severity, according to KDIGO classification, was stage 1 (47%), stage 2 (21%), and stage 3 (31%). Higher stages had earlier onset acute kidney injury, a lower percentage of returning to baseline, and exposure to a higher colistin dose. Conclusion: Colistin-induced nephrotoxicity was a frequent issue associated with higher weights, mitigated by the combination with carbapenems. While higher colistin dosages, and earlier onset AKI, were linked to the progression to higher AKI stages and the need for dialysis.